An angiotensin II receptor blocker increases sexual behavior in type 2 diabetic mice

2007 ◽  
Vol 91 (2-3) ◽  
pp. 223-228 ◽  
Author(s):  
Masayoshi Nomura ◽  
Hisae Nishii ◽  
Yumi Ozaki ◽  
Naohiro Fujimoto ◽  
Tetsuro Matsumoto
Keyword(s):  
Sexual Behavior ◽  
Angiotensin Ii ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Diabetic Mice ◽  
Angiotensin Ii Receptor ◽  
Type 2 Diabetic

scholarly journals Management of Home Blood Pressure by Amlodipine Combined With Angiotensin II Receptor Blocker in Type 2 Diabetes

2012 ◽  
Vol 76 (9) ◽  
pp. 2159-2166 ◽  
Author(s):  
Katsumi Miyauchi ◽  
Tsutomu Yamazaki ◽  
Hirotaka Watada ◽  
Yasushi Tanaka ◽  
Ryuzo Kawamori ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Angiotensin Ii ◽  
Home Blood Pressure ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor

Effect of angiotensin II receptor blocker and salt supplementation on short-term blood pressure variability in type 2 diabetes

2019 ◽  
Vol 34 (2) ◽  
pp. 143-150
Author(s):  
Angela X. Chen ◽  
John L. Moran ◽  
Renata Libianto ◽  
Sara Baqar ◽  
Christopher O’Callaghan ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Angiotensin Ii ◽  
Blood Pressure Variability ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Short Term

Abstract 2221: Long-Term Administration of Thiazolidinedione Provides Multiple Ultrasonic Manifested Antiatherosclerotic Effects Independent of Diabetic Improvement for Type-2 Diabetics Receiving Angiotensin-II Receptor Blocker

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Tatsuaki Murakami ◽  
Katsushi Misawa
Keyword(s):  
Angiotensin Ii ◽  
Brachial Artery ◽  
Receptor Blocker ◽  
Diabetic Patients ◽  
Angiotensin Ii Receptor Blocker ◽  
Sublingual Administration ◽  
Angiotensin Ii Receptor ◽  
Type 2 Diabetics

Background: Insulin resistance and type-2 diabetes mellitus are thought to be highly involved in complex atherothrombogenic processes, but the long-term effects of insulin sensitizing agents remain partially clarified. We assessed hypothesis that long-term use of thiazolidinedione, an insulin sensitizer, pleiotropically inhibits atherosclerotic progression in patients treated with angiotensin-II receptor blocker, one of the best possible antiatherosclerotic therapies. Methods: Thirty-two type-2 diabetic patients treated with angiotensin-II receptor blocker were randomized to group-T where they received troglitazone (400mg/day) or pioglitazone (30mg/ day), or to group-C where they continued therapy without thiazolidinedione for more than 2 years. We quantified flow-mediated dilation of brachial artery after 5 minutes forearm occlusion (FMD), dilation of brachial artery after sublingual administration of nitroglycerin (TNG), and intima-media thickness of common carotid artery (IMT) using high-resolution ultrasonography. Changes in FMD, TNG, and IMT were compared between the 2 groups. Results: Group-T (n=16) manifested improvements in diabetic variables while group-C showed no improvement. FMD (%) increased after medication in group-T (p<0.01) but remained unchanged in group-C (p=0.86). TNG (%) remained unchanged in both groups. IMT (mm) decreased in group-T (p=0.03) but remained unchanged in group-C (p=0.12). Changes of FMD or IMT in group-T did not correlate to those of HbA1c (FMD: r=0.21, p=0.70, IMT: r=0.22, p=0.62). Conclusion: These results indicate long-term therapy with thiazolidinedione in diabetic patients receiving angiotensin-II receptor blocker additionally improves endothelial function, and reduces arterial wall thickness independent of reversal for diabetic status, which may have novel potential benefit for management of atherosclerosis in type-2 diabetics treated with standard antiatherosclerotic therapies.

Sign in / Sign up

Export Citation Format

Share Document